Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVANAT + 5-FU in Advanced Biliary Cancer
NCT00386516Phase 2Withdrawn
- Sponsor
- Galectin Therapeutics
- Start
- Sep 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Davanat in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Galectin Therapeutics. Primary endpoints: Objective Response Rate, Stable Disease Rate and 1 more. Planned start Sep 2006; status: withdrawn.
02
Drugs
Davanat
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT00386516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386516.